Quarterly financial information

Onxeo Provides Strategy Update and Reports 2017 Third Quarter Financial Information

Company completes strategic shift to innovative DNA-targeting programs and platON™ chemistry platform of decoy oligonucleotides Development of lead product AsiDNA™ in line with plans Paris (France), October 26, 2017 – 08:00 pm CEST– Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – ISIN FR0010095596), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology,…read more →

Onxeo Reports First-Half 2017 Results and Business Update

Sound cash position of €27.7m as at June 30, 2017 and cash runway till Q1 2019 Development of the core assets on track with multiple short-term milestones Livatag® Phase III results expected before the end of September 2017 Preclinical results of Beleodaq® in other indications / combinations expected by the end of September 2017 AsiDNA™ (systemic administration) Phase I trial…read more →

Onxeo: Q1 2017 financial information and business update

    Revenues up 55% to €1.2 million     Cash position of €21.7 million at March 31, 2017     All strategic assets are progressing according to development plans   Paris, April 26, 2017 – 6.30 pm CEST. Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in…read more →

Onxeo Reports Third Quarter 2016 Financial Information and Provides Business Update

Clinical development plan in line with objectives Livatag® on track to deliver its next important milestone with 90% of patients randomized  €12.5m capital increase successfully completed Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today published its consolidated financials for the period ending September 30, 2016…read more →

Onxeo First Quarter 2016 Financial Information and Business Update // DANISH TRANSLATION: Onxeo informerer om sine resultater og forretningsmæssige tiltag i 1. kvartal 2016

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Pipeline reinforced through major development milestones on existing assets and new product acquisition Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today provided an update on financial results and major milestones achieved during the first quarter of 2016, ending March…read more →

Onxeo Reports First Half 2015 Business Update and Consolidated Accounts – Onxeo informerer om sine forretningsmæssige tiltag og resultatet for 1. halvår 2015

Livatag® Phase III trial in HCC: 50% of patients randomized Scientific recognition of Validive® and Beleodaq® preclinical and clinical data at ASCO Annual  Meeting and MASCC/ISOO International Symposium Sound financial position with €42.9 million cash  Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today reported its consolidated half-year accounts as…read more →

Quarterly Information as of March 31, 2015 – Kvartalsmeddelelse pr. 31. marts 2015

       Significant advancements of company programs                   – Livatag®: Opening of new centres and active recruitment in the ReLive trial                  – Validive®: Presentation of positive preliminary results of the Phase II trial at ASCO                  – Beleodaq®: new steps in the product development        Strengthened internal organization        Strong visibility in terms of cash Paris (France), Copenhagen (Denmark), April…read more →

2014 Onxeo Review and 2015 Perspectives 2014 – Consolidated Financial Results – Onxeo – årsresultat for 2014 og forventninger til 2015 Regnskabsberetning for 2014

2014 Onxeo Review and 2015 Perspectives 2014 Consolidated Financial Results -       Successful strategic merger and acquisition of Danish company Topotarget giving birth to Onxeo -       Products’ major achievements .   Beleodaq® approval in the US for PTCL 2nd line treatment and launch by US partner .   Validive® phase II positive data -       FY 2014: proforma net profit of €7.3m (excluding one-time…read more →

Quarterly Information as of September 30, 2014

Quarterly Information as of September 30, 2014 – Effective integration of both entities, BioAlliance Pharma and Topotarget, into newly named Onxeo – Major advancements of company programs • Validive®: Positive preliminary top-results of the Phase II trial • Beleodaq®: Grant of U.S. marketing authorization and first sales • Livatag®: Active recruitment in the ReLive trial with nearly 35% of planned…read more →

Key milestones and consolidated accounts – First six months 2014 / Vigtige milepæle og koncernregnskab 1. halvår 2014

Major evolution of the Company, renamed Onxeo, resulting from the merger between BioAlliance Pharma and Topotarget Good progress of the major portfolio products Financial resources strengthened and expenses controlled Paris (France), Copenhagen (Denmark), August 1, 2014 – Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specialized in the development of drugs for orphan oncology diseases, today…read more →

Quarterly information as of March 31, 2014

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today published a summary of the key events of the first quarter of 2014, as well as its consolidated revenues for the quarter. Key orphan oncology programs Validive® and Livatag® have successfully reached important milestones during the first quarter of…read more →

Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013

Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing agreement signed for US Income growth and operating costs under control. Paris, April 15, 2013 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products and to supportive care products today…read more →